April 28, 2020Open Access

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Key Points

Key points are not available for this paper at this time.

Abstract

The combination of regorafenib 80 mg plus nivolumab had a manageable safety profile and encouraging antitumor activity in patients with gastric and colorectal cancer, which warrants additional investigations in larger cohorts.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Shota Fukuoka

Hiroki Hara

Naoki Takahashi

Journals

Journal of Clinical Oncology

Actions

Institutions

National Cancer Center Hospital East

Saitama Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study